MediClin AG (XTER:MED) Tariff Resilience Score: 0/10 (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTER:MED MediClin AG XTER:MED
79 GF Score
Price €4.08
GF Value €3.04
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is MediClin AG Tariff Resilience Score?

MediClin AG has the Tariff Resilience Score of 0, which implies that the company might have .

MediClin AG has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes MediClin AG might have .

MediClin AG  (XTER:MED) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

MediClin AG Tariff Resilience Score Related Terms

XTER:MED
79GF Score
MediClin AG XTER:MED
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is MediClin AG (XTER:MED) Overvalued in 2026?

Based on GuruFocus' analysis, MediClin AG stock appears to be overvalued. The current stock price of €4.08 is trading 34.2% above its estimated GF Value™ of €3.04. GuruFocus considers MediClin AG to be Significantly Overvalued.

Key valuation signals for XTER:MED:

  • Tariff Resilience Score: 0
  • GF Value™: €3.04 vs. price of €4.08 (34.2% above fair value)
  • GF Score™: 79/100 with 5 warning signs

No single metric tells the full story. See the XTER:MED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MediClin AG Business Description

Other Exchanges 0NDG:UK
Address Okenstrasse 27, Offenburg, BW, DEU, 77652
MediClin AG operates hospitals and other medical care centers. The company's reportable operating segments are the Post-acute, Acute, Nursing care, and Service segments. A majority of its revenue is generated from the Post-acute segment, which offers services in the fields of follow-up rehabilitation treatment and curative treatment. Some of the post-acute hospitals also offer services in acute neurology and acute psychosomatics. The Acute segment encompasses medical offerings with a focus on neurology and neurological early rehabilitation as well as psychosomatic medicine, psychiatry, orthopaedics, and internal medicine. The Nursing care segment offers full-time and part-time nursing care as well as daycare, and the Service segment consists of the central services.
79GF Score

Get the complete analysis for XTER:MED

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.08
Price
€3.04
GF Value